Regeneron’s US Eylea Sales Increase 14 Percent in Q4-2017

February 9, 2018: By Jon Swedien


Net sales of Eylea (aflibercept) in the US totaled $975 million in Q4-2017, a 14 percent increase over Q4-2016 revenues of $858 million, Regeneron reported Feb. 8.

The Tarrytown, New York, company reported that net sales of Eylea for the full year were $3.7 billion, an 11 percent increase over the 2016 total.

Bayer commercializes Eylea outside the US. Its net sales of Eylea outside of the US in Q4-2017 were $637 million, a 28 percent increase over the Q4-2016 total, Regeneron said.

Net sales outside the US for the full year were more than $2.2 billion, a 19 percent increase over the 2016 total of $1.9 billion, Regeneron said.

Regeneron recognized $231 million in Q4-2017 from its share of net profit from Eylea sales outside the US, up from $165 million in Q4-2016. For the full year, Regeneron recognized $802 million, up from $649 million in 2016.

Regeneron posted $1.6 billion in revenues in Q4-2017, compared with $1.2 billion in Q4-2016, a 29 percent increase.

The company posted $5.9 billion in revenues for all of 2017, a 21 percent increase over the $4.9 billion it posted in 2016.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US FDA Approves Icon Bioscience’s DEXYCU for Post-Cataract Surgery Inflammation

FDA’s Gottlieb Appears to Soften Stance on Compounding for Office Use

Genentech’s RG7716 Outperformed Ranibizumab in Phase II Study in Diabetic Macular Edema

Santen Reports Promising Data in Phase I/II Study in Refractory Wet AMD

Q Biomed Signs Agreement with Washington University for Novel Biomarker for Monitoring Glaucoma

pSivida’s Durasert for Posterior Segment Uveitis Yields Positive 12-Month Results in Second Phase III Study

Foundation Fighting Blindness Provides $7.5 Million to Help Develop ProQR’s Candidate for Usher Syndrome

Presbia Names Casey Lind as Chief Operating Officer, Magda Michna, MD, PhD, as Chief Clinical Officer

Astellas Acquires Universal Cells

Pixium Vision Completes Two Successful PRIMA Implantations in Atrophic Dry AMD Patients

Omeros Loses Pass-through Status for Omidria

USC Donations Drop $100 Million after Puliafito Scandal, Report Says

Regeneron’s US Eylea Sales Increase 14 Percent in Q4-2017

Allergan’s Net Sales Climb 12 Percent in Q4-2017; Restasis Sales Grow Nearly 1 Percent

Lucentis’ US Sales Drop 11 percent in Q4-2017, Grow 1 Percent for Full 2017

EyeGate’s EGP-437 for Post-Cataract Pain, Inflammation Produces Mixed Results in Phase IIb Trial

Second Sight Reports Record Number of Argus II Implants in Q4-2017, First Orion Implant in Human

Allergan Appoints Matthew Walsh as CFO

Ocunova Secures $500 Thousand From Two Firms to Pursue Dry Eye Treatment for Diabetic Patients

ReVision Optics Closes Doors; Raindrop Corneal Inlay No Longer Available

Coming soon

2018 Retinal Surgical Devices Report: A Global Market Analysis for 2017 to 2023